Zebinix: new for epilepsy

Zebinix (eslicarbazepine acetate) has been launched as an adjunctive treatment for partial-onset seizures with or without secondary generalisation.

Eslicarbazepine acetate is a carboxamide derivative.

The drug's exact mechanism of action is unknown, but it is suggested that it works by stabilising the inactivated state of voltage-gated sodium channels, preventing their return to the activated state therefore sustaining repetitive neuronal firing.

Zebinix must be added to existing anticonvulsant therapy and the dose increased gradually. Zebinix is licensed for the management of epilepsy in adults; caution should be exercised when managing elderly patients and it is not recommended for use in children.

View Zebinix drug record

Further information: Eisai

To sign up for the MIMS monthly news update, register at www.mims.co.uk/bulletins.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more